Xenetic Biosciences Inc XBIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma
-
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
-
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
-
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
Trading Information
- Previous Close Price
- $2.81
- Day Range
- $2.77–2.95
- 52-Week Range
- $1.90–13.93
- Bid/Ask
- $2.75 / $3.05
- Shares Outstanding
- 2.29M
- Market Cap
- $6.37M
- Volume/Avg
- 13,892 / 16,221
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.65
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 2
- Website
- https://www.xeneticbio.com
Valuation
|
Metric
|
XBIO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.92 |
Price/Sales | 1.65 |
Price/Cash Flow | — |
Price/Earnings
XBIO
Financial Strength
|
Metric
|
XBIO
|
|---|---|
Quick Ratio | 7.67 |
Current Ratio | 7.93 |
Interest Coverage | — |
Quick Ratio
XBIO
Profitability
|
Metric
|
XBIO
|
|---|---|
Return on Assets (Normalized) | −33.51% |
Return on Equity (Normalized) | −39.06% |
Return on Invested Capital (Normalized) | −41.82% |
Return on Assets
XBIO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|k%y!^Y | LOCK|xdvK& | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|WMl&v<# | LOCK|!p$< | $71B | |||
| argenx SE ADR
ARGX
| LOCK|<X?%%$@ | LOCK|R& | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|mMPq?S% | LOCK|w!p | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|@&P&r!$ | LOCK|W$>@? | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$%FB>VZ | LOCK|>?%%@ | $26B | |||
| Moderna Inc
MRNA
| LOCK|Rj>FyL% | LOCK|C! | $25B | |||
| Incyte Corp
INCY
| LOCK|%%&S>WT | LOCK|b$? | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|H%@B>D | LOCK|Zg | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|$vhCg! | LOCK|KX | $16B |
United States